TCGA-A2-A3XT-01A-11R-A22U-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 92
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.590
- ALLOGRAFT_REJECTION+0.450
- E2F_TARGETS+0.440
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.430
- MYC_TARGETS_V1+0.380
- IL6_JAK_STAT3_SIGNALING+0.350
- INFLAMMATORY_RESPONSE+0.340
- G2M_CHECKPOINT+0.330
- INTERFERON_GAMMA_RESPONSE+0.290
- OXIDATIVE_PHOSPHORYLATION+0.290
Top 10 suppressed
- PROTEIN_SECRETION-0.420
- TGF_BETA_SIGNALING-0.410
- ANDROGEN_RESPONSE-0.390
- UV_RESPONSE_DN-0.360
- ESTROGEN_RESPONSE_EARLY-0.340
- ANGIOGENESIS-0.280
- APICAL_SURFACE-0.270
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.260
- ESTROGEN_RESPONSE_LATE-0.260
- APOPTOSIS-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AC-A6IW-01A-12R-A33J-07 | — | E | 0.887 |
| 2 | TCGA-B6-A0IJ-01A-11R-A034-07 | — | E | 0.869 |
| 3 | TCGA-A2-A3Y0-01A-11R-A239-07 | — | E | 0.848 |
| 4 | TCGA-A7-A6VW-01A-21R-A33J-07 | — | E | 0.842 |
| 5 | TCGA-AO-A129-01A-21R-A10J-07 | — | E | 0.838 |
| 6 | TCGA-EW-A6SB-01A-12R-A32P-07 | — | E | 0.837 |
| 7 | TCGA-AR-A1AQ-01A-11R-A12P-07 | — | E | 0.835 |
| 8 | TCGA-A2-A0D0-01A-11R-A00Z-07 | — | E | 0.817 |
| 9 | TCGA-BH-A1F6-01A-11R-A13Q-07 | — | E | 0.816 |
| 10 | TCGA-C8-A12K-01A-21R-A115-07 | — | E | 0.815 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.590 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.450 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.440 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.430 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.380 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.340 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.330 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.290 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.290 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.260 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.250 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.220 | Inavolisib | — uncovered |
| COAGULATION | 0.210 | Binimetinib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.150 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.130 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.120 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.120 | Inavolisib | — uncovered |